NTRA – Natera, Inc.

NTRA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.99

Margin Of Safety %

-24

Put/Call OI Ratio

0.61

EPS Next Q Diff

0.15

EPS Last/This Y

-0.21

EPS This/Next Y

1.08

Price

204.08

Target Price

260.72

Analyst Recom

1.3

Performance Q

-3.52

Upside

-128.1%

Beta

1.55

Ticker: NTRA

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-13	NTRA	201.93	0.93	10.92	23963
2026-04-14	NTRA	214.74	0.92	1.57	21467
2026-04-15	NTRA	207	0.94	0.17	21997
2026-04-17	NTRA	208.53	0.65	2.01	28387
2026-04-20	NTRA	207.84	0.65	0.51	24058
2026-04-21	NTRA	205.25	0.71	4.64	22983
2026-04-23	NTRA	201.12	0.72	0.13	23410
2026-04-24	NTRA	204.03	0.67	0.80	25602
2026-04-27	NTRA	204.49	0.67	0.37	25650
2026-04-28	NTRA	200.16	0.67	0.08	25666
2026-04-29	NTRA	195.02	0.66	0.16	25836
2026-04-30	NTRA	206.34	0.65	0.70	26120
2026-05-01	NTRA	207.25	0.65	0.21	26192
2026-05-04	NTRA	211.55	0.65	0.09	26278
2026-05-05	NTRA	206.96	0.66	0.02	26127
2026-05-06	NTRA	215.09	0.65	1.10	26396
2026-05-07	NTRA	219.7	0.67	0.40	26747
2026-05-08	NTRA	194.21	0.63	1.18	28279
2026-05-11	NTRA	199.46	0.64	0.47	28817
2026-05-12	NTRA	204.06	0.61	0.16	28891
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-13	NTRA	201.91	-12.1	-21.1	-1.89
2026-04-14	NTRA	214.66	-12.1	-25.9	-1.89
2026-04-15	NTRA	207.17	-12.1	1.6	-1.89
2026-04-16	NTRA	196.08	-12.1	6.9	-1.89
2026-04-17	NTRA	208.62	-12.1	-26.1	-1.89
2026-04-20	NTRA	207.76	-10.6	-7.3	-1.86
2026-04-21	NTRA	205.33	-10.6	-4.9	-1.85
2026-04-22	NTRA	207.68	-10.6	-11.3	-1.85
2026-04-23	NTRA	201.24	-10.6	0.6	-1.85
2026-04-24	NTRA	204.03	-10.6	-12.2	-1.85
2026-04-27	NTRA	204.50	-10.6	-9.2	-1.85
2026-04-28	NTRA	200.20	-10.6	-2.4	-1.85
2026-04-30	NTRA	206.43	-10.6	-25.0	-1.85
2026-05-01	NTRA	207.22	-10.6	-9.6	-1.85
2026-05-04	NTRA	211.67	-10.6	-14.1	-1.85
2026-05-05	NTRA	206.89	-10.6	-2.0	-1.85
2026-05-06	NTRA	215.01	-10.6	-19.2	-1.85
2026-05-07	NTRA	219.00	-10.6	-13.3	-1.85
2026-05-08	NTRA	194.16	-10.6	24.5	-1.85
2026-05-11	NTRA	199.27	27.5	2.7	-1.85
2026-05-12	NTRA	204.08	16.6	3.9	-1.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-13	NTRA	-12.68	0.81	3.61
2026-04-14	NTRA	-12.68	0.81	3.61
2026-04-15	NTRA	-12.68	0.81	3.61
2026-04-16	NTRA	-12.68	0.81	3.61
2026-04-17	NTRA	-12.68	0.81	3.61
2026-04-20	NTRA	-12.63	0.86	3.61
2026-04-21	NTRA	-12.63	0.86	3.61
2026-04-22	NTRA	-12.65	0.86	3.62
2026-04-23	NTRA	-12.13	0.86	3.62
2026-04-24	NTRA	-12.13	0.86	3.62
2026-04-27	NTRA	-12.10	0.77	2.80
2026-04-28	NTRA	-12.10	0.77	2.80
2026-04-29	NTRA	-12.10	0.77	2.80
2026-04-30	NTRA	-12.13	0.77	2.80
2026-05-01	NTRA	-12.13	0.77	2.80
2026-05-04	NTRA	-10.16	0.76	2.80
2026-05-05	NTRA	-9.86	0.76	2.80
2026-05-06	NTRA	-9.93	0.76	2.80
2026-05-07	NTRA	-10.01	0.76	2.80
2026-05-08	NTRA	-10.01	0.76	2.80
2026-05-11	NTRA	-10.01	1.02	2.80
2026-05-12	NTRA	-10.03	1.02	2.99
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.6

Avg. EPS Est. Current Quarter

-0.62

Avg. EPS Est. Next Quarter

-0.45

Insider Transactions

-10.03

Institutional Transactions

1.02

Beta

1.55

Average Sales Estimate Current Quarter

654

Average Sales Estimate Next Quarter

688

Fair Value

155.74

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

20.4

Max Drawdown 5-Year %

-77.7

Target Price

260.72

P/E

Forward P/E

PEG

P/S

11.69

P/B

16.43

P/Free Cash Flow

279.84

EPS

-1.64

Average EPS Est. Cur. Y

-1.73

EPS Next Y. (Est.)

-0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.05

Relative Volume

1.18

Return on Equity vs Sector %

-39.6

Return on Equity vs Industry %

-24

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.16

EBIT Estimation

3.9

◆ NTRA Healthcare

$204.21

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

10/20

Pullback

13/25

Volume

1/15

Valuation

10/20

TP/AR

3/10

Options

6/10

RSI

49.8

Range 1M

45.6%

Sup Dist

5.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

14/30

Estimates

4/20

Inst/Vol

6/15

Options

8/10

EPS Yr

-6.5%

EPS NY

78.4%

52W%

58.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -3.1% upside

Quality

6/30

Valuation

1/30

Growth

10/25

Stability

9/10

LT Trend

2/5

Upside

-3.1%

Quality

MoS

-24%

Natera, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 6135

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

NTRA

Latest News

—

Caricamento notizie per NTRA…

stock quote shares NTRA – Natera, Inc. Stock Price stock today

news today NTRA – Natera, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NTRA – Natera, Inc. yahoo finance google finance

stock history NTRA – Natera, Inc. invest stock market

stock prices NTRA premarket after hours

ticker NTRA fair value insiders trading

NTRA – Natera, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NTRA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y